Monitoring vascular normalization induced by antiangiogenic treatment with 18F-fluoromisonidazole-PET

Molecular Oncology

Volumn 10, Issue 5, 2016, Pages 704-718

  Hernández Agudo, Elena ^a   Mondejar, Tamara ^a   Soto Montenegro, Maria Luisa ^b,c   Megías, Diego ^a   Mouron, Silvana ^a   Sanchez, Jesus ^a   Hidalgo, Manuel ^a   Lopez Casas, Pedro Pablo ^a   Mulero, Francisca ^a   Desco, Manuel ^b,c,d   Quintela Fandino, Miguel ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d UNIVERSIDAD CARLOS III DE MADRID   (Spain)

Author keywords

18F misonidazole PET; Antiangiogenics; Biomarker; Breast cancer; Pancreatic cancer; Vascular normalization

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; CASPASE 3; DOVITINIB; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; KI 67 ANTIGEN; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 4-AMINO-5-FLUORO-3-(5-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL)QUINOLIN-2(1H)-ONE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC ANTIMETABOLITE; BENZIMIDAZOLE DERIVATIVE; DEOXYCYTIDINE; FLUORINE; MISONIDAZOLE; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PARAMETERS; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL DEATH; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG DETERMINATION; DRUG DOSE REDUCTION; DRUG POTENCY; FEMALE; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT DURATION; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VASCULAR NORMALIZATION; ANALOGS AND DERIVATIVES; ANIMAL; BREAST; BREAST NEOPLASMS; CELL HYPOXIA; DIAGNOSTIC IMAGING; DRUG EFFECTS; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PANCREAS; PANCREATIC NEOPLASMS; TUMOR CELL LINE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BENZIMIDAZOLES; BREAST; BREAST NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; DEOXYCYTIDINE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MICE; MICE, NUDE; MISONIDAZOLE; NEOVASCULARIZATION, PATHOLOGIC; PANCREAS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; QUINOLONES;

EID: 84953438859     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.12.011     Document Type: Article

References (41)

1. Bruehlmeier M., Roelcke U., Schubiger P.A., Ametamey S.M. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. J. Nucl. Med. 2004, 45:1851-1859.
2. Burger R.A., Brady M.F., Bookman M.A., Fleming G.F., Monk B.J., Huang H., Mannel R.S., Homesley H.D., Fowler J., Greer B.E., Boente M., Birrer M.J., Liang S.X. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 2011, 365:2473-2483. Gynecologic Oncology, G.
3. Chen Z.Y., Shi M., Peng L.X., Wei W., Li X.J., Guo Z.X., Li S.H., Zhong C., Qian C.N., Guo R.P. Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis. J. Transl Med. 2012, 10:245.
4. Cobleigh M.A., Langmuir V.K., Sledge G.W., Miller K.D., Haney L., Novotny W.F., Reimann J.D., Vassel A. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol. 2003, 30:117-124.
5. Eschmann S.M., Paulsen F., Bedeshem C., Machulla H.J., Hehr T., Bamberg M., Bares R. Hypoxia-imaging with (18)F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother. Oncol. 2007, 83:406-410.
6. Eschmann S.M., Paulsen F., Reimold M., Dittmann H., Welz S., Reischl G., Machulla H.J., Bares R. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J. Nucl. Med. 2005, 46:253-260.
7. Ferl G.Z., Port R.E. Quantification of antiangiogenic and antivascular drug activity by kinetic analysis of DCE-MRI data. Clin. Pharmacol. Ther. 2012, 92:118-124.
8. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
9. Francia G., Cruz-Munoz W., Man S., Xu P., Kerbel R.S. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat. Rev. Cancer 2011, 11:135-141.
10. Franco M., Man S., Chen L., Emmenegger U., Shaked Y., Cheung A.M., Brown A.S., Hicklin D.J., Foster F.S., Kerbel R.S. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res. 2006, 66:3639-3648.
11. Gagel B., Reinartz P., Demirel C., Kaiser H.J., Zimny M., Piroth M., Pinkawa M., Stanzel S., Asadpour B., Hamacher K., Coenen H.H., Buell U., Eble M.J. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 2006, 6:51.
12. Gilkes D.M., Semenza G.L., Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat. Rev. Cancer 2014, 14:430-439.
13. Hlatky L., Hahnfeldt P., Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl. Cancer Inst. 2002, 94:883-893.
14. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
15. Huynh H., Chow P.K., Tai W.M., Choo S.P., Chung A.Y., Ong H.S., Soo K.C., Ong R., Linnartz R., Shi M.M. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J. Hepatol. 2012, 56:595-601.
16. Jain R. Measurements of tumor vascular leakiness using DCE in brain tumors: clinical applications. NMR Biomed. 2013, 26:1042-1049.
17. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
18. Jain R.K. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat. Rev. Cancer 2008, 8:309-316.
19. Jain R.K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol. 2013, 31:2205-2218.
20. Kerbel R.S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 2006, 312:1171-1175.
21. Kerbel R.S. Reappraising antiangiogenic therapy for breast cancer. Breast 2011, 20(Suppl. 3):S56-S60.
22. Kerbel R.S. Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer. J. Mammary Gland Biol. Neoplasia 2012, 17:229-239.
23. Kerbel R.S., Guerin E., Francia G., Xu P., Lee C.R., Ebos J.M., Man S. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis. Breast 2013, 22(Suppl. 2):S57-S65.
24. Lawler P.R., Lawler J. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect. Med. 2012, 2. a006627.
25. Lee S.H., Lopes de Menezes D., Vora J., Harris A., Ye H., Nordahl L., Garrett E., Samara E., Aukerman S.L., Gelb A.B., Heise C. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin. Cancer Res. 2005, 11:3633-3641.
26. Limaverde-Sousa G., Sternberg C., Ferreira C.G. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents. Cancer Treat Rev. 2014, 40:548-557.
27. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., Shenkier T., Cella D., Davidson N.E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 2007, 357:2666-2676.
28. Perren T.J., Swart A.M., Pfisterer J., Ledermann J.A., Pujade-Lauraine E., Kristensen G., Carey M.S., Beale P., Cervantes A., Kurzeder C., du Bois A., Sehouli J., Kimmig R., Stahle A., Collinson F., Essapen S., Gourley C., Lortholary A., Selle F., Mirza M.R., Leminen A., Plante M., Stark D., Qian W., Parmar M.K., Oza A.M., Investigators I. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 2011, 365:2484-2496.
29. Petrillo M., Scambia G., Ferrandina G. Novel targets for VEGF-independent anti-angiogenic drugs. Expert Opin. Investig. Drugs 2012, 21:451-472.
30. Richey S.L., Hutson T.E. Angiopoietins and non-vascular endothelial growth factor antiangiogenic targets in advanced renal cell carcinoma. Cancer J. 2013, 19:307-310.
31. Rischin D., Hicks R.J., Fisher R., Binns D., Corry J., Porceddu S., Peters L.J. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J. Clin. Oncol. 2006, 24:2098-2104.
32. Rischin D., Hicks R.J., Fisher R., Binns D., Corry J., Porceddu S., Peters L.J. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J. Clin. Oncol. 2006, 24:2098-2104. Trans-Tasman Radiation Oncology Group, S.
33. Rolny C., Mazzone M., Tugues S., Laoui D., Johansson I., Coulon C., Squadrito M.L., Segura I., Li X., Knevels E., Costa S., Vinckier S., Dresselaer T., Akerud P., De Mol M., Salomaki H., Phillipson M., Wyns S., Larsson E., Buysschaert I., Botling J., Himmelreich U., Van Ginderachter J.A., De Palma M., Dewerchin M., Claesson-Welsh L., Carmeliet P. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011, 19:31-44.
34. Rubio-Viqueira B., Jimeno A., Cusatis G., Zhang X., Iacobuzio-Donahue C., Karikari C., Shi C., Danenberg K., Danenberg P.V., Kuramochi H., Tanaka K., Singh S., Salimi-Moosavi H., Bouraoud N., Amador M.L., Altiok S., Kulesza P., Yeo C., Messersmith W., Eshleman J., Hruban R.H., Maitra A., Hidalgo M. An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res. 2006, 12:4652-4661.
35. Sakurai T., Kudo M. Signaling pathways governing tumor angiogenesis. Oncology 2011, 81(Suppl. 1):24-29.
36. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R., Johnson D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355:2542-2550.
37. Sharpless N.E., Depinho R.A. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov. 2006, 5:741-754.
38. Van der Veldt A.A., Lubberink M., Bahce I., Walraven M., de Boer M.P., Greuter H.N., Hendrikse N.H., Eriksson J., Windhorst A.D., Postmus P.E., Verheul H.M., Serne E.H., Lammertsma A.A., Smit E.F. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012, 21:82-91.
39. Wang J., Foehrenbacher A., Su J., Patel R., Hay M.P., Hicks K.O., Wilson W.R. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia. Clin. Cancer Res. 2012, 18:1684-1695.
40. Yan M., Lesyk G., Radziwon-Balicka A., Jurasz P. Pharmacological regulation of platelet factors that influence tumor angiogenesis. Semin. Oncol. 2014, 41:370-377.
41. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., Steinberg S.M., Chen H.X., Rosenberg S.A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003, 349:427-434.